Adolore biotherapeutics strengthens management team and board of directors with the appointments of roelof rongen, mse, mba and mark c. rogers, md, mba

Mr. rongen appointed as ceo and member of the board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areas bolstered expertise on board of directors with addition of dr. rogers who brings significant leadership and expertise spanning both public and private sectors in health care and the biopharmaceutical industry delray beach, fl / accesswire / january 17, 2023 / adolore biotherapeutics, inc. ("adolore" or the "company"), a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for chronic pain, today announced the appointments of roelof rongen, mse, mba as chief executive officer and director, and mark c. rogers, md, mba as a member of the company's board of directors.
MTNB Ratings Summary
MTNB Quant Ranking